AllTranz is a specialty pharmaceutical company developing a unique set of dermal delivery products utilizing two proprietary technology platforms consisting of prodrug development and microneedle formulations. AllTranz will be a leader in the development of innovative drug design strategies delivered via unique dermal product solutions to treat neurological and a variety of other disorders. The broad range of offerings includes solutions for pain modulation, appetite stimulation, smoking cessation, substitution treatment for opiate addiction, as well as alcohol abuse, and abuse deterrent formulations for opiates. AllTranz will utilize its unique dermal drug delivery technology to develop its own products for broad market appeal, as well as partner with pharmaceutical companies seeking to leverage the AllTranz technology platform to improve delivery of existing drugs to form new chemical entities thereby extending patent franchises.
The AllTranz product portfolio targets large and growing markets with suboptimal or unmet medical need. All of the AllTranz product have indications in the pain management market, was valued at $46.4 Billion in 2011[1] and expected to reach $60 Billion by 2015[2]. The THC prodrug patch product has wide ranging applications including pain management, treatment of nausea and vomiting from cancer chemotherapy, significant weight loss in patients with HIV/AIDS, pain relief, and muscle stiffness in patients with MS. This product can also address the growing medical marijuana market, which is estimated at $1.7B in 2011 and will reach $8.9B in just five years[3]. The CBD gel product is targeted for moderate to severe pain, specifically focusing on the osteoarthritis market segment. Osteoarthritis is a significant disease both in terms of incidence and prevalence, affecting 27 million Americans. The size of the osteoarthritis prescription drug market, valued at $5 Billion worldwide in 2009 and is expected to grow to $5.5 Billion by 2016, demonstrates the depth and breadth of this disease[4]. The BUP product also has broad market appeal for treating pain and opiate addiction with a valuable abuse deterrent component. The microneedle product has numerous applications in pain and other indications because it is capable of delivering small and large molecules for extended periods of time.
